Introduction
Interest increases in adoptive immunotherapy using genetically redirected T cells on demonstration of their therapeutic efficacy in the treatment of malignant diseases. [1] [2] [3] [4] Patient-derived T cells are retrovirally engineered ex vivo to express a recombinant T-cell receptor or, alternatively, a chimeric antigen receptor (CAR, immunoreceptor), amplified and re-infused to recognize and to destroy tumour lesions by their cytolytic capacities. In contrast to recombinant T-cell receptors, CARs consist of a single polypeptide chain with an antibody-derived single chain fragment (scFv) in the extracellular moiety for binding and the CD3z or combined CD28-CD3z signalling domain in the intracellular moiety for T-cell activation. 5, 6 During the last years, a variety of CARs with different scFv-binding domains have been generated. These CARs harbour binding specificities for cancer-and leukaemia-associated antigens, such as carcinoembryonic antigen (CEA), melanoma-associated antigens, CD30 and CD19, or for virus-infected cells, such as human immunodeficiency virus and hepatitis B. An increasing number of clinical trials with engineered T cells recognizing defined target antigens on tumour cells are going to be initiated. Although of different specificity, the modular composition of most CARs is quite similar. A common structural property is a spacer domain interposed between the extracellular scFv moiety and the transmembrane domain, which seems to be mandatory for stable and functional expression of several CD3z signalling CARs in T cells. 7, 8 The constant IgG1 hinge-CH2-CH3 Fc domain is most commonly used as spacer domain resulting in dimerization and thereby increasing CAR expression on the cell surface. The Fc domain is moreover expected to be of low immunogenicity contributing to increase the half-life of circulating T cells with CAR expression. The Fc domain is also used for CAR detection on the cell surface and enrichment of engineered cells by cell sorting procedures.
We 
Results
We generated CARs of the same backbone but with different scFv-binding domains, that is, HRS3 scFv specific for CD30 and BW431/26 scFv specific for CEA ( Figure 1 To avoid unintended cross-activation of FcgR + cells, we modified the IgG1 Fc domain in the extracellular domain of the anti-CD30 CAR by mutation of both the PELLGG and ISR motif (Figure 3a ). These amino acids, known to be essential for IgG1-FcgR interactions, 9, 10 were replaced by the corresponding IgG2 amino acids. Modified FcD CARs were expressed on the surface of T cells with similar efficacies as CARs with wild-type Fc domain (Figure 3b ). To record activation, redirected anti-CD30 T cells were co-incubated with FcgR + THP-1 cells, which do not express CD30. As summarized in Figure 3c , engineered T cells with modified FcD CAR were not activated by binding to THP-1 cells indicated by lack of IFN-g increase which is in contrast to T cells with the Fc wild-type CAR. Accordingly, THP-1 cells were not lysed by engineered T cells with the modified FcD anti-CD30 CAR in contrast to co-incubation with T cells with the anti-CD30 wild-type Fc CAR. Moreover, THP-1 cells were not cross-activated in presence of T cells with the modified FcD CAR indicated by lack of increase in IL-1b secretion. We obtained similar results using T cells which were engineered with the modified anti-CEA CAR (data not shown).
To assure that Fc modification did not alter scFv redirected effector functions, we incubated engineered T cells on solid phase bound scFv ligands. As summarized in Figure 4a , T cells expressing the wild-type or the modified anti-CD30 CAR were activated to IFN-g secretion by a set of solid phase bound internal and noninternal anti-HRS3 idiotypic mAbs as well as by solid phase bound CD30 but not by an isotype IgG1 or an irrelevant anti-idiotypic mAb. In contrast, engineered T cells with the corresponding set of anti-CEA CARs were activated by the respective anti-idiotypic mAb directed against the anti-CEA-binding domain but not by the anti-HRS3 idiotypic mAbs. Moreover, wild-type and 
Discussion
Previous studies highlight the requirement of a spacer domain inserted between the scFv binding and transmembrane domain in CD3z signalling CARs for stable expression on the surface of T cells. 7, 8 On the basis of these observations the IgG1 CH2CH3 (Fc) domain is commonly used as extracellular spacer in a broad variety of CARs. In this study, we revealed, however, that CARs A common set of IgG1 CH2 residues is involved in binding to all Fcg receptors although FcgRII and FcgRIII can also use residues beside this common set. 9, 10 As a consequence, we modified the IgG1 Fc spacer in the CH2 domain by replacing IgG1 residues, which are predominantly involved in FcgR interaction by IgG2 amino acids. Previously used to engineer IgG constant domains that lack killing through FcgR, 11 replacements were restricted to motifs from other Ig subclasses to minimize potential immunogenicity. In particular, IgG2 residues that replace IgG1 residues at positions 233-236 reduced binding to FcgRI by 10 4 -fold. 11 Integrated into Although unintended elimination of FcgR + cells by activated T cells is not expected to have severe clinical consequences, 'off-target' activation of engineered T cell may result in rapid loss of anti-tumour activity because of activation-induced cell death. Forthcoming studies using CARs of the scFv-Fc-CD3z or scFv-Fc-CD28-CD3z format, however, likely benefit from modification of the IgG1 spacer domain to avoid unintended 'off-target' activation of engineered T cells. Non-myeloablative conditioning, which is mandatory before adoptive transfer to sustain engineered T-cell expansion 14 will reduce monocytes and NK cells in numbers along with others, at least in circulation. Pre-conditioning will thereby minimize the risk of unintended activation of engineered T cells as long as the number of those cells is reduced. On bone marrow regeneration, however, increasing numbers of FcgR + cells will increase the risk of 'off-target' activation as well as rapid elimination of engineered T cells. In long term, therefore, adoptive immunotherapy with engineered T cells will substantially benefit from modification of the IgG1 Fc spacer domain.
Materials and methods

Cell lines and reagents
293T cells are human embryonic kidney cells that express the SV40 large T antigen. 15 The colon carcinoma cell lines LS174T (ATCC CCL 188), SW948 (ATCC CCL 237) and H716 (ATCC CCL-251) and the human acute monocytic leukaemia cell line THP-1 (ATCC TIB-202) were obtained from ATCC, Rockville, MD, USA. The CD30 + lymphoma line MyLa was kindly provided by Professor R Dummer, Zurich. The CD30 + Hodgkin lymphoma cell line L1236 was described earlier. 16 MC38 is a fibrosarcoma cell line, which was transfected to express CEA (C15A3) and CD30, respectively. 17 All cell lines were cultured in RPMI 1640 medium, 10% (v/v) fetal calf serum (all Life Technologies, Paisly, UK). Anti-CD3 mAb OKT3 was purified from OKT3 hybridoma (ATCC CRL 8001) by affinity chromatography. The anti-HRS3 idiotypic antibodies 9G10, 12D3, 14B9 and 14G9 carrying internal and non-internal image epitopes were described elsewhere. 18 The phycoerythrin (PE)-conjugated F(ab 0 )2 goat antihuman IgG antibody was purchased from Southern Biotechnology (Birmingham, Alabama, USA), the fluorescein isothiocyanate-conjugated anti-CD3 mAb UCHT-1, the fluorescein isothiocyanate-conjugated anti-CD32 mAb KB61 and the PE-conjugated anti-CD64 mAb 10.1 from Dako, Glostrup, Denmark. The allophycocyanin (APC)-conjugated anti-CD3 mAb UCHT-1, the PE-conjugated anti-CD16 mAb3G8, the fluorescein isothiocyanate-conjugated anti-CD107a mAb H4A3 and the fluorochromeconjugated isotype controls were purchased from BD Bioscience, San Diego, CA, USA; the PE-labelled anti-CD30 mAb (Ki-2) and Fc-blocking reagent from Miltenyi Biotech (Bergisch Gladbach, Germany). The anti-human IFN-g mAb NIB42 and the biotinylated anti-human IFN-g mAb 4S.B3 were both purchased from BD Bioscience. Recombinant IL-2 was obtained from Endogen, Woburn, MA, USA. Immunofluorescence was analyzed using a fluorescence-activated cell sorting Canto cytofluorometer equipped with the Diva software (Becton Dickinson, Mountain View, CA, USA). À NK cells were individually gated by flow cytometry and cytolytic activation of the respective cells was recorded by monitoring CD107a expression. The assay was performed three times, a representative assay is shown.
Modification of chimeric antigen receptors
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Generation of CARs
The anti-CEA CAR BW431/26scFv-Fc-CD28-CD3z contains the CEA-specific binding domain BW431/ 26scFv and a modified intracellular domain for combined CD28-CD3z signalling. The anti-CD30 CAR HRS3scFv-Fc-CD28-CD3z was generated by substitution of the CEA-specific BW431/26scFv domain by the CD30-specific HRS3scFv domain. HRS3scFv-FcD-CD28-CD3z (anti-CD30-FcD-CAR) was generated by site directed modification of the anti-CD30 CAR by PCR using the sense oligonucleotide primer 5 0 -TGCGCAG CACCTCCAGTCGCGGGACCGTCAGTCTTCCTCTTCC CCCCAAAACCCAAGGACACCCTCATGATCGCCCG GACCCCT-3 0 and the antisense oligonucleotide primer 5 0 -AGGGGTCCGGGCGATCATGAGGGTGTCCTTGGGT TTTGGGGGGAAGAGGAAGACTGACGGTCCCGCGAC TGGAGGTGCTGCGCA-3 0 . The modified anti-CEA CAR BW431/26scFv-FcD-CD28-CD3z (anti-CEA-FcD-CAR) was obtained by substitution of the wild-type Fc sequence by the modified Fc sequence. Retroviral transduction of T cells with recombinant receptors was elsewhere described in detail. 15, [19] [20] [21] [22] Receptor expression was monitored by flow cytometry.
Magnetic-activated cell sorting
Peripheral blood lymphocytes from healthy donors were isolated by density centrifugation and monocytes were depleted by plastic adherence. Non-adherent lymphocytes were washed with cold phosphate-buffered saline containing 0.5% (w/v) bovine serum albumin, 1% (v/v) fetal calf serum and 2 mM EDTA. CD3 + T cells were isolated by magnetic-activated cell sorting using the 'Pan T-cell isolation Kit II human' and NK cells using the 'NK cell isolation Kit human' (both Miltenyi Biotech) to purities of routinely 495%. CAR modified T cells and 3 Â 10 5 autologous NK cells were co-incubated for 16 h and stained with the fluorescein isothiocyanate-conjugated anti-CD107a mAb H4A3 (BD Bioscience). Cells were stained with the PE-conjugated anti-CD16 and APC-conjugated anti-CD3 antibody and analyzed by flow cytometry. IFN-g and IL-1b were detected by enzyme-linked immunosorbent assay using matched pairs of antibodies (BD Bioscience). Briefly, IFN-g in culture supernatants was bound to the solid phase capture antibody (1 mg ml -1 ) and detected by the biotinylated detection antibody (0.5 mg ml -1 ).
Redirected activation of engineered T cells
The reaction product was visualized by a peroxidasestreptavidin conjugate (1:10 000) and 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS). IL-1b was recorded using the 'BD OptEIA Set Human IL-1b' according to the manufacturer's recommendation.
